Table 2.
Groups of patients based on the treatment given during the first month after diagnosis: Contribution to the treatment groups by the participating countries, baseline characteristics, and additional therapy
| Characteristic | Oral CYC | Intravenous CYC | Rituximab | Steroids Only | Otherd | Untreated |
|---|---|---|---|---|---|---|
| Participants | 35.4 (46) | 30.8 (40) | 12.3 (16) | 1.5 (2) | 14.6 (19) | 5.4 (7) |
| Countries | ||||||
| Sweden (n=81) | 30.9 (25/81) | 35.8 (29/81) | 8.6 (7/81) | 2.5 (2/81) | 14.8 (12/81) | 7.4 (6/81) |
| United Kingdom (n=25) | 52.0 (13/25) | 0.0 (0/25) | 36.0 (9/25) | 0.0 (0/25) | 12.0 (3/25) | 0.0 (0/25) |
| Czech Republic (n=24) | 33.3 (8/24) | 45.8 (11/24) | 0.0 (0/24) | 0.0 (0/24) | 16.7 (4/24) | 4.2 (1/24) |
| Clinical variables | ||||||
| Age (yr) | 79 (77–81) | 78 (77–81) | 79 (78–81) | 78 (76–79) | 83 (78–85) | 80 (77–81) |
| MPOa | 76.1 (35/46) | 59.0 (23/39) | 37.5 (6/16) | 100 (2/2) | 47.4 (9/19) | 85.7 (6/7) |
| PR3a | 21.7 (10/46) | 41.0 (16/39) | 56.3 (9/16) | 0.0 (0/2) | 52.6 (10/19) | 14.3 (1/7) |
| Creatinine (mg/dl)b | 4.04 (2.68–4.92) | 2.00 (1.13–3.69) | 3.01 (2.00–4.28) | 8.89 (2.29–15.49) | 4.02 (2.69–5.96) | 2.99 (2.05–6.24) |
| Dialysisa | 37.8 (17/45) | 17.5 (7/40) | 31.3 (5/16) | 50.0 (1/2) | 26.3 (5/19) | 28.6 (2/7) |
| BVASa | 14 (12–19) | 15 (14–20) | 14 (9–21) | 15 (14–15) | 16 (13–19) | 12 (5–17) |
| Comorbiditiesc | 71.7 (33/46) | 57.5 (23/40) | 50.0 (8/16) | 0.0 (0/2) | 63.2 (12/19) | 71.4 (5/7) |
| Treatment variables | ||||||
| Pulse steroids | 28.3 (13/46) | 55.0 (22/40) | 56.3 (9/16) | 0.0 (0/2) | 31.6 (6/19) | 0.0 (0/7) |
| Plasma exchange1 | 26.1 (12/46) | 27.5 (11/40) | 46.7 (7/15) | 50.0 (1/2) | 26.3 (5/19) | 14.3 (1/7) |
Values are presented as % (n) or median (interquartile range) and exclude missing data. MPO, myeloperoxidase; PR3, proteinase-3; BVAS, Birmingham Vasculitis Activity Score; CYC, cyclophosphamide.
a
Data missing in one patient.
b
Data missing in six patients.
c
Patients with ≥1 comorbid condition at diagnosis.
d
Other cytotoxic agents or cumulative cyclophosphamide dose <2000 mg oral cyclophosphamide/<1500 mg intravenous cyclophosphamide during the first 3 months.